Merzianu Mihai, Jiang Liuyan, Lin Pei, Wang Xuemei, Weber Donna M, Vadhan-Raj Saroj, Nguyen Martin H, Medeiros L Jeffrey, Bueso-Ramos Carlos E
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Mod Pathol. 2006 Jul;19(7):891-8. doi: 10.1038/modpathol.3800609. Epub 2006 Apr 21.
B-cell lymphoma 10 (BCL-10) is expressed in the cytoplasm of normal germinal center and marginal zone B-cells and is involved in lymphocyte development and activation. Aberrant nuclear expression of BCL-10 occurs in a subset of extranodal marginal zone B-cell lymphomas (MALT lymphomas), primarily those with the t(1;14)(p22;q32) or t(11;18)(q21;q21). Little is known about BCL-10 expression in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM). We assessed for BCL-10 in 51 bone marrow (BM) specimens involved by LPL/WM using immunohistochemical methods. All patients had monoclonal IgM in serum. Extent of BM involvement was assessed using PAX-5/BSAP and CD20 immunostains and the pattern and percentage of B-cells positive for BCL-10 was determined. The p65 subunit of nuclear factor-kappa B (NF-kappaB), a molecule downstream of BCL-10, was also assessed immunohistochemically. Nuclear BCL-10 staining was present in 28/51 (55%) specimens. BCL-10 expression correlated with greater extent of BM involvement (P=0.001), but did not correlate with serum IgM paraprotein levels, type of immunoglobulin light chain, or clinical variables. Nuclear expression of the p65 subunit of NF-kappaB was detected in 17/50 (34%) specimens, suggesting that NF-kappaB is active in a subset of LPL/WM. p65 NF-kappaB activation did not correlate with nuclear BCL-10 immunostaining. Cytogenetic analysis in 29 cases showed no evidence of the t(1;14) or t(11;18). These results indicate that nuclear BCL-10 expression is common in LPL/WM and does not correlate with MALT lymphoma-associated translocations or p65 NF-kappaB nuclear staining.
B细胞淋巴瘤10（BCL-10）在正常生发中心和边缘区B细胞的细胞质中表达，参与淋巴细胞的发育和激活。BCL-10的异常核表达出现在一部分结外边缘区B细胞淋巴瘤（黏膜相关淋巴组织淋巴瘤）中，主要是那些具有t(1;14)(p22;q32)或t(11;18)(q21;q21)的病例。关于BCL-10在淋巴浆细胞性淋巴瘤/华氏巨球蛋白血症（LPL/WM）中的表达情况知之甚少。我们采用免疫组化方法对51例LPL/WM累及的骨髓（BM）标本进行了BCL-10检测。所有患者血清中均有单克隆IgM。采用PAX-5/BSAP和CD20免疫染色评估骨髓受累程度，并确定BCL-10阳性B细胞的模式和百分比。还通过免疫组化方法评估了BCL-10下游分子核因子κB（NF-κB）的p65亚基。5l例标本中有28例（55%）出现核BCL-10染色。BCL-10表达与骨髓受累程度加重相关（P=0.001），但与血清IgM副蛋白水平、免疫球蛋白轻链类型或临床变量无关。在50例标本中有17例（34%）检测到NF-κB p65亚基的核表达，提示NF-κB在一部分LPL/WM中具有活性。p65 NF-κB激活与核BCL-10免疫染色无关。29例的细胞遗传学分析未发现t(1;14)或t(11;18)的证据。这些结果表明，核BCL-10表达在LPL/WM中很常见，且与黏膜相关淋巴组织淋巴瘤相关的易位或p65 NF-κB核染色无关。
